- Combination of ONCOS-102 and Keytruda reduces size of
non-injected tumors
- In vivo proof-of-concept of ONCOS-102 ability to generate
systemic anti-tumor responses
OSLO, Norway, June 3, 2019 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage biotechnology company
developing immune activators to target hard-to-treat solid tumors,
today announces that a study showing abscopal effect of ONCOS-102
and Keytruda combination treatment in a humanized mouse melanoma
model has been accepted for publication in the Journal of Medical
Virology.
Targovax has previously published anti-tumor efficacy of
ONCOS-102 as monotherapy as well as synergy with both chemotherapy
and checkpoint inhibitors in mouse models. It has also been
demonstrated in several different animal models how ONCOS-102
induces robust immune responses and can generate de novo
tumor specific T-cells recognizing relevant cancer antigens.
In this latest publication, Targovax has been able to build on
the previous immune activation and anti-tumor findings by showing
that the combination of ONOCS-102 and Keytruda can generate
systemic responses that reduce the size of non-injected lesions.
The work was performed in a humanized melanoma mouse model with
tumors inoculated dorsally on both sides of the animals. After the
tumors were established, ONCOS-102 was injected directly into the
tumor on one side only, followed by systemic treatment with
Keytruda. By Day 40, tumors on the non-injected side of the animals
had shrunk by an average of 70%. This confirms the hypothesis that
ONCOS-102 is able to generate systemic immune responses, which can
lead to abscopal anti-tumor effect of distal lesions that have not
been injected with the virus.
Magnus Jäderberg, Chief Medical Officer of Targovax,
said: "This in vivo demonstration of abscopal
effect is an important validation of the proposed mechanism of
action of ONCOS-102. By injecting the virus intra-tumorally, we see
not only a local oncolytic effect at the injection site, but also a
reduction of tumors in other locations. As such, these findings
provide an in vivo proof-of-concept of ONCOS-102's
ability to generate systemic anti-cancer immune responses"
Publication title: Abscopal effect when combining
oncolytic adenovirus and checkpoint inhibitor in a humanized NOG
mouse model of melanoma
Link:
https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25501
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum
Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-announces-publication-of-in-vivo-abscopal-effect-of-oncos-102-and-keytruda-combination,c2830521